82 related articles for article (PubMed ID: 38539538)
1. Salivary Duct Carcinoma: An Update on Morphologic Mimics and Diagnostic Use of Androgen Receptor Immunohistochemistry.
Udager AM; Chiosea SI
Head Neck Pathol; 2017 Sep; 11(3):288-294. PubMed ID: 28321773
[TBL] [Abstract][Full Text] [Related]
2. Immunoprofiles and Oncologic Outcomes of 15 Patients with Androgen Receptor-Positive Salivary Duct Carcinoma.
Gogineni E; Sells BE; Dibs K; Jhawar SR; Haring CT; Limbach AL; Konieczkowski DJ; Ma SJ; Zhu S; Baliga S; Mitchell DL; Grecula JC; Bonomi M; Bhateja P; Old MO; Seim NB; Kang SY; Rocco JW; Chakravarti A; Blakaj DM; Gamez ME
Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539538
[TBL] [Abstract][Full Text] [Related]
3. The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers.
Hanna GJ; Bae JE; Lorch JH; Haddad RI; Jo VY; Schoenfeld JD; Margalit DN; Tishler RB; Goguen LA; Annino DJ; Chau NG
Oncologist; 2020 Jul; 25(7):598-608. PubMed ID: 32310325
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features and treatment outcomes of the rare, salivary duct carcinoma of parotid gland.
Al-Qahtani KH; Tunio MA; Bayoumi Y; Gurusamy VM; Bahamdain FA; Fatani H
J Otolaryngol Head Neck Surg; 2016 May; 45(1):32. PubMed ID: 27184361
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
[TBL] [Abstract][Full Text] [Related]
7. Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature.
Poxleitner P; Shoumariyeh K; Steybe D; Hupfer V; Voss PJ; Rawluk J; Ermer M; Miething C; Schmelzeisen R; Duyster J
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):599-603. PubMed ID: 31904529
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant versus Concurrent Androgen Deprivation Therapy in Localized Prostate Cancer Treated with Radiotherapy: A Systematic Review of the Literature.
Cartes R; Karim MU; Tisseverasinghe S; Tolba M; Bahoric B; Anidjar M; McPherson V; Probst S; Rompré-Brodeur A; Niazi T
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444473
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic Factors and Their Association with Outcomes of Salivary Duct Carcinoma: A Multicenter Experience.
Laughlin BS; Ebrahimi S; Voss MM; Patel SH; Foote RL; McGee LA; Garcia J; Ma DJ; Garces YI; Wittich MAN; Price KA; Schmitt A; Zhai Q; May BC; Nagel TH; Hinni ML; Chintakuntlawar AV; DeWees TA; Rwigema JM
Adv Radiat Oncol; 2023; 8(4):101204. PubMed ID: 37152485
[TBL] [Abstract][Full Text] [Related]
10. Loss of Estrogen Receptors is Associated with Increased Tumor Aggression in Laryngeal Squamous Cell Carcinoma.
Verma A; Schwartz N; Cohen DJ; Patel V; Nageris B; Bachar G; Boyan BD; Schwartz Z
Sci Rep; 2020 Mar; 10(1):4227. PubMed ID: 32144339
[TBL] [Abstract][Full Text] [Related]
11. Intensity Modulated Radiotherapy (IMRT) With Carbon Ion Boost in the Multimodal Treatment of Salivary Duct Carcinoma.
Adeberg S; Windisch P; Ehret F; Baur M; Akbaba S; Held T; Bernhardt D; Haefner MF; Krauss J; Kargus S; Freudlsperger C; Plinkert P; Flechtenmacher C; Herfarth K; Debus J; Rieken S
Front Oncol; 2019; 9():1420. PubMed ID: 31921675
[No Abstract] [Full Text] [Related]
12. Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.
Murthy RK; Loi S; Okines A; Paplomata E; Hamilton E; Hurvitz SA; Lin NU; Borges V; Abramson V; Anders C; Bedard PL; Oliveira M; Jakobsen E; Bachelot T; Shachar SS; Müller V; Braga S; Duhoux FP; Greil R; Cameron D; Carey LA; Curigliano G; Gelmon K; Hortobagyi G; Krop I; Loibl S; Pegram M; Slamon D; Palanca-Wessels MC; Walker L; Feng W; Winer EP
N Engl J Med; 2020 Feb; 382(7):597-609. PubMed ID: 31825569
[TBL] [Abstract][Full Text] [Related]
13. Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Tolaney SM; Guo H; Pernas S; Barry WT; Dillon DA; Ritterhouse L; Schneider BP; Shen F; Fuhrman K; Baltay M; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis MJ; Shapira I; Wolff AC; Carey LA; Overmoyer B; Partridge AH; Hudis CA; Krop IE; Burstein HJ; Winer EP
J Clin Oncol; 2019 Aug; 37(22):1868-1875. PubMed ID: 30939096
[TBL] [Abstract][Full Text] [Related]
14. Association of Estrogen Receptor Alpha Expression With Survival in Oropharyngeal Cancer Following Chemoradiation Therapy.
Koenigs MB; Lefranc-Torres A; Bonilla-Velez J; Patel KB; Hayes DN; Glomski K; Busse PM; Chan AW; Clark JR; Deschler DG; Emerick KS; Hammon RJ; Wirth LJ; Lin DT; Mroz EA; Faquin WC; Rocco JW
J Natl Cancer Inst; 2019 Sep; 111(9):933-942. PubMed ID: 30715409
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
